Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy.
Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy.
复制标题
肝细胞癌的磁共振成像生物标志物：与舒尼替尼治疗后的反应和循环生物标志物的关联
DOI：
10.1186/1756-8722-6-51
复制
发表时间：
2013-07-10
影响因子：
28.5
通讯作者：
Zhu AX
中科院分区：
文献类型：
--
作者：
Sahani DV;Jiang T;Hayano K;Duda DG;Catalano OA;Ancukiewicz M;Jain RK;Zhu AX
目的探讨磁共振弥散加权成像(DWI)和灌注成像(MRP)参数是监测晚期肝细胞癌(HCC)早期抗血管生成效应和预测无进展生存期(PFS)的敏感图像生物标志物的假设。在这项II期临床试验中，34名患者中有23名纳入了成像和循环生物标记物研究。分别于服药前和服药后2周进行磁共振弥散加权成像(DWI)和磁共振成像(MRP)。成像方案包括使用b值为50、400和800秒/mm2的轴向DWI序列，以及在以2ml/秒的速度注射20ml Gd-DTPA后使用一系列冠状3D-Vibe的MRP。将这些参数与6个月后的临床结果和PFS进行比较。还评估了MRI参数变化与血浆生物标记物之间的相关性。经舒尼替尼治疗2周后，肝细胞癌组织中KTRANS由基线中值2.15min−1增至0.94min−1(P = 0.0001)，表观扩散系数由0.88 × 10-3mm2/S增至0.98mm2× × 10-3mm2/S(P = 0.0001)。RECIST和mRECIST的肿瘤大小保持不变(均为P >； 0.05)。2周时KTRANS和KEP下降较大的患者与良好的临床结局相关，而基线KTRANS和EVF下降较大的患者与较长的PFS相关(均P <； 0.05)。SVEGFR2的下降与Ktras、KEP的下降显著相关(P = 0.044，P = 0.030)；肿瘤坏死因子-α的下降与Ktran、KEP的下降密切相关(P = 0.051，P = 0.035)。在肝细胞癌中，MRP可能是一个比RECIST和mRECIST更敏感的生物标志物，可以预测舒尼替尼治疗后的早期反应和PFS。ClinicalTrials.gov：NCT00361309
To investigate the hypothesis that MRI derived diffusion-weighted imaging (DWI) and perfusion (MRP) parameters are sensitive image biomarkers for monitoring early antiangiogenic effects and predicting progression free survival (PFS) in advanced hepatocellular carcinoma (HCC). In this phase II clinical trial, 23 of 34 patients were included in the imaging and circulating biomarker study. DWI and MRP were performed at the baseline and at 2-weeks after initiation of sunitinib. The imaging protocol included an axial DWI sequence using b values of 50, 400 and 800 sec/mm2, and MRP using a series of coronal 3D-VIBE following 20 ml of Gd-DTPA at 2 ml/sec. These parameters were compared with clinical outcome and PFS at 6-months. Correlation between changes in MRI parameters and plasma biomarkers was also evaluated. After 2-week of sunitinib, substantial Ktrans changes in HCC were observed from median baseline value 2.15 min−1 to 0.94 min−1 (P = 0.0001) with increases in median apparent diffusion coefficient (ADC) from 0.88 × 10-3 mm2/s to 0.98 × 10-3 mm2/s (P = 0.0001). Tumor size remained unchanged by RECIST and mRECIST (both P > 0.05). Patients who showed larger drop in Ktrans and Kep at 2 weeks correlated with favorable clinical outcome, and higher baseline Ktrans and larger drop in EVF correlated with longer PFS (all P < 0.05). There was a significant association between a decrease in sVEGFR2 and the drop in Ktrans and Kep (P = 0.044, P = 0.030), and a significant and borderline association between decrease in TNF-α and the drop in Ktrans and Kep, respectively (P = 0.051, P = 0.035). In HCC, MRP may be a more sensitive biomarker in predicting early response and PFS following sunitinib than RECIST and mRECIST. ClinicalTrials.gov: NCT00361309
登录
查看更多内容
影响因子：
25.7
作者：
Hsu, Chao-Yu;Shen, Ying-Chun;Shih, Tiffany Ting-Fang
通讯作者：
Shih, Tiffany Ting-Fang
影响因子：
51.1
作者：
Faivre, Sandrine;Raymond, Eric;Cheng, Ann Lii
通讯作者：
Cheng, Ann Lii
分子机制和血管生成的临床应用。
影响因子：
64.8
作者：
Carmeliet, Peter;Jain, Rakesh K.
通讯作者：
Jain, Rakesh K.
影响因子：
5
作者：
Koh, Dow-Mu;Scurr, Erica;Husband, Janet E.
通讯作者：
Husband, Janet E.
影响因子：
45.3
作者：
Motzer, RJ;Michaelson, MD;Rini, BI
通讯作者：
Rini, BI